Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

American Urological Association (AUA) annual meeting in San Antonio strongly emphasized diversity, equity, and inclusion, as ...

VMPL Chennai Tamil Nadu [India] December 23 Kauvery Hospital Vadapalani a leading healthcare institution in Chennai has ...

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...

The first target for this plasmid is non-muscle invasive bladder cancer (NMIBC), which is currently managed primarily with ...

ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment ...

(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of ...

Protara Therapeutics reports promising Phase 2 results for TARA-002 in bladder cancer patients, highlighting high response rates and strong safety data.

Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.